Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EPC2407: Interim Phase I data

In an ongoing open-label, U.S. Phase I trial, intravenous EPC2407 stabilized disease in

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE